Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Kwok

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Rheumatology and Therapy|July 17, 2023
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid ArthritisGerd R Burmester, Laura C Coates, Stanley B Cohen, et al.
The Journal of Rheumatology|November 17, 2017
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III StudiesChristina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, et al.
Health Promotion International|April 23, 2025
Involving children in global health policy and programming: practical guidance to get startedGabrielle Mathews, Bethany Jennings, Sarah Sterlini, et al.
International Journal of Rheumatic Diseases|March 23, 2019
Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study dataEun Bong Lee, Hisashi Yamanaka, Yi Liu, et al.
Arthritis Research & Therapy|April 7, 2019
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension studyJürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R Curtis, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 23, 2014
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritisStanley Cohen, Sebastião C Radominski, Juan J Gomez-Reino, et al.
Rheumatology and Therapy|January 21, 2026
Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc AnalysisTsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, et al.
Reumatologia Clinica|June 19, 2016
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studiesSebastião Cezar Radominski, Mario Humberto Cardiel, Gustavo Citera, et al.
Journal of Ophthalmology|August 27, 2011
Comparison of newly diagnosed ocular hypertension and open-angle glaucoma: ocular variables, risk factors, and disease severityYvonne M Buys, Paul Harasymowycz, Rania Gaspo, et al.
RMD Open|April 12, 2024
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety studyMaya H Buch, Deepak L Bhatt, Christina Charles-Schoeman, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Rheumatology and Therapy|July 17, 2023
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid ArthritisGerd R Burmester, Laura C Coates, Stanley B Cohen, et al.
The Journal of Rheumatology|November 17, 2017
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III StudiesChristina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, et al.
Health Promotion International|April 23, 2025
Involving children in global health policy and programming: practical guidance to get startedGabrielle Mathews, Bethany Jennings, Sarah Sterlini, et al.
International Journal of Rheumatic Diseases|March 23, 2019
Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study dataEun Bong Lee, Hisashi Yamanaka, Yi Liu, et al.
Arthritis Research & Therapy|April 7, 2019
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension studyJürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R Curtis, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 23, 2014
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritisStanley Cohen, Sebastião C Radominski, Juan J Gomez-Reino, et al.
Rheumatology and Therapy|January 21, 2026
Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc AnalysisTsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, et al.
Reumatologia Clinica|June 19, 2016
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studiesSebastião Cezar Radominski, Mario Humberto Cardiel, Gustavo Citera, et al.
Journal of Ophthalmology|August 27, 2011
Comparison of newly diagnosed ocular hypertension and open-angle glaucoma: ocular variables, risk factors, and disease severityYvonne M Buys, Paul Harasymowycz, Rania Gaspo, et al.
RMD Open|April 12, 2024
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety studyMaya H Buch, Deepak L Bhatt, Christina Charles-Schoeman, et al.
Pageof 6